Additionally, PHA665752, a drug that blocks MET phosphorylation, has shown to be effective in targeting NRAS-mutant cells during in vitro studies, indicating the broader effectiveness of Met inhibitors in treating various melanoma subtypes, not only the common BRAFV600E mutant [72]. Here, MET is linked to melanoma.